FDA Approves First-Ever Agent to Delay Type 1 Diabetes Onset

Teplizumab delayed progression to clinical type 1 diabetes by about 2 years compared with placebo in individuals destined to develop the condition because of autoantibody levels.

Related Keywords

United States ,American ,Emilyk Sims ,Ashleigh Palmer ,John Sharretts ,Provention Bio ,Division Of Diabetes ,Indiana University School Of Medicine ,Drug Administration ,Department Of Pediatrics ,American Diabetes Association ,Lipid Disorders ,Drug Evaluation ,Onset Delayed ,New England Journal ,Science Translational Medicine ,Indiana University School ,Diabetes Mellitus Type 1 ,Iabetes Mellitus Type I ,Type 1 Diabetes ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Intravenous Iv ,Intravenous ,Tv ,Preventive Screening ,Screening ,Adverse Effects ,Side Effects ,Blood ,Cytokines ,Diabetes Research ,Esearch In Diabetes ,Disease Modifying Therapy ,Mt ,Endocrinology ,Ndocrine System ,Europe ,European ,Leukopenia ,Monoclonal Antibody ,Etuximab ,Ituximab ,